Common use of Development Costs Clause in Contracts

Development Costs. With respect to activities prior to the Amendment Effective Date, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.

Development Costs. With The Parties will share equally all Development Costs for the ADC (which have been set forth in the Clinical Work Plan) with respect to the Development activities prior hereunder. The Parties are obligated to each fund fifty percent (50%) of costs associated with the Amendment Effective DateDevelopment of the ADC up until the final report for the Qualifying Phase I/II Clinical Trial. Notwithstanding the above, each Party was to pay in the event that the manufacturer of the ADC chosen by ADCT is not [**], the Parties agree that ADCT will be solely responsible for the payment of (a) the [**] of [**], and (b) the total Direct [**] of [**]. Also, notwithstanding anything to the contrary in this Agreement, if a certain milestone for [**] of [**] becomes payable to [**] while the Parties are Co-Developing, the Parties agree that ADCT will be responsible for the payment of [**] of such milestone and Genmab will be responsible for the payment of [**] of such milestone. The JSC shall review on a [**] basis the Development Costs against the budget for such expenses in the applicable calendar year. If in the course of such [**] review the JSC determines that the actual amounts incurred for Development Costs are likely to be higher than budgeted, the JSC shall review the reasons for such potential overrun and determine whether such overrun is appropriate. The JSC may, if appropriate, amend the Clinical Work Plan to permit such overrun or to reduce such activities such that no overrun is incurred. If any costs for the Development activities result in a Product incurred budget overrun of the applicable and approved annual joint budget in excess of [**], the JSC shall have the discretion to review such costs and designate them as Development Costs. Where the JSC does not so designate excess Development Costs, any such unapproved excess Joint Development Costs shall be borne by the Party incurring them. However, if the budget overrun is due to a delay or an advance in timing as to the planned activities, which activities are in accordance with the Clinical Work Plan, then such excess Development Budget (as defined in Costs shall be shared equally by the Original Parties regardless of which Party has incurred such costs. ADCT agrees that payments under the Spirogen Agreement), if any, shall not be part of the Development Costs and shall be borne solely by ADCT. Notwithstanding anything Certain confidential information contained in this Article 6 of this Agreement or in any other provision of this Agreement to document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, information (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs is not material and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder would likely cause competitive harm to ADC Therapeutics SA (ADCT) if publicly disclosed. Section 7.2 is deleted in its entirety and replaced with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera following (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, blacklines showing change from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.original):

Development Costs. With respect to Except as provided in Section 4.3, PRAECIS shall pay seventy-five percent (75%), and Synthelabo shall pay twenty-five percent (25%), of all Development Costs incurred in carrying out the Core Development Plan. The foregoing cost sharing provisions shall also apply if PRAECIS enters into an agreement with a Third Party under which such Third Party shall undertake PRAECIS' development activities prior pursuant to the Amendment Effective DateCore Development Plan, each Party was unless PRAECIS and Synthelabo shall agree otherwise. Synthelabo shall pay all Development Costs which are incurred in carrying out the Supplemental Development Plan, provided that PRAECIS shall reimburse Synthelabo for seventy-five percent (75%) of such Development Costs to pay [*] the extent the results of the total Direct Development Phase activities in respect of which such Development Costs were incurred are used to seek or obtain Registration Approvals or Reimbursement Approvals in the United States. If (i) PRAECIS or its licensee or sublicensee wishes to use both outside of a Product the Territory and outside of the United States the results of the Supplemental Development Studies obtained by Synthelabo in carrying out the Supplemental Development Plan and (ii) PRAECIS is not required hereunder to reimburse Synthelabo 75% of the Development Costs incurred in accordance connection with the such Supplemental Development Budget (as defined Studies, then PRAECIS and Synthelabo shall meet to negotiate in the Original Agreement). Notwithstanding anything in this Article 6 good faith an equitable sharing of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct such Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement Anything herein to the contrarycontrary notwithstanding, (i) all payments owing each of Synthelabo and PRAECIS shall have full and complete access to and use of the safety data of the other regarding each Licensed Product, and each may use the safety data of the other for Advertising and Promotion, in each case without any cost or reimbursement therefor and (ii) regulatory submission, registration fees and maintenance fees in the Territory shall be paid by CDS hereunder with respect Synthelabo, and registration fees and maintenance fees 40 outside the Territory shall be paid by PRAECIS. If a party is claiming reimbursement pursuant to development activities prior this Section 4.5, then within forty-five (45) days after the end of a calendar quarter during which the Development Costs for which reimbursement is being claimed were incurred, a party will submit to the Amendment Effective Date are hereby deemed fully other a statement (each a "Development Cost Statement") itemizing in reasonable detail such Development Costs and setting forth the total amount, if any, of such Development Costs to be reimbursed by the other party pursuant to this Section 4.5. Such reimbursement amounts shall be paid by CDS within twenty (or waived20) days after receipt of a Development Cost Statement, except to the extent such waiver may be required)Development Cost Statement is being disputed in good faith. Except as otherwise provided herein, including any each party shall assume full responsibility for its own Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforCosts.

Development Costs. With (a) During the Early Clinical Development Term, SGI will reimburse Unum for [***] of all Development Costs for all Development Candidates actually incurred for the Territory pursuant to the Early Clinical Development Plan, in accordance with Section 11.5, subject to the following sentence. Notwithstanding the amounts allocated to Development activities in the Shared Territory in the applicable Early Clinical Development Plan budget, for any calendar year, Unum will only be permitted to recover Development Costs with respect to Development activities prior that have been [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED allocated to Unum under the Amendment Effective Date, each Party was Early Clinical Development Plan and related budget in excess of the amount allocated therein (i) by up to pay [***] of the total Direct amount so allocated, or (ii) with the unanimous approval of the JDC, which approval may be granted either in advance of such costs being incurred or retroactively. For clarity, during the Early Clinical Development Term, Unum will not be required to incur any Development Costs of a Product incurred in accordance with the for any Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera Candidates for which SGI will be solely responsible fornot reimburse Unum, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct SGI will not be required to reimburse Unum for any Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing Costs not approved by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, SGI as and to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original required under this Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.

Development Costs. With respect to activities If prior to the Amendment Effective DateCommencement Date Transporter terminates this Agreement under Sections 5(A)(iv) or 5(A)(vi) or Shipper terminates this Agreement under Section 5(D)(iii) , each Party was to then Shipper shall pay [*] Transporter the actual costs reasonably incurred and/or committed by Transporter for the development of the total Direct Project (“Development Costs”). The Development Costs shall include, but shall not be limited to, all costs associated with the following activities: (i) participating in the FERC pre-filing process; (ii) preparing and filing Transporter’s application for a FERC Certificate; (iii) developing, designing, surveying, and performing studies to define the scope of a Product the Project; (iv) developing the design and engineering of the Project Facilities; (v) preparing all drawings, maps, reports, and schedules necessary to be included in Transporter’s application for the FERC Certificate; (vi) contacting and meeting with any and all stakeholders to gain support for, or to appease opposition to, the Project; (vii) preparing, filing, and processing all relevant applications for Transporter Regulatory Authorizations; (viii) identifying the suitability of the property on which the Project Facilities will be constructed and any construction areas that will be needed as part of the Project; and (ix) acquisition of equipment and materials for the construction any portion of the Project Facilities. To the extent that Shipper owes Transporter for Development Costs as provided in this Section 3(E), not later than ninety (90) days following the termination of this Agreement, Transporter shall deliver an invoice (“Invoice”) to Shipper for all Development Costs incurred in accordance with the terms hereof. The Invoice shall set forth all charges and credits (in United States Dollars) summarized by appropriate classifications indicating the nature of the charges. Within thirty (30) days after the receipt of the Invoice, Shipper shall pay Transporter all Development Budget (as defined Costs set forth in the Original AgreementInvoice. To the extent Transporter, using commercially reasonable efforts, is able to mitigate any of the Development Costs during a period of time that extends six (6) months from the date this Precedent Agreement is terminated (“Mitigation”). Notwithstanding anything in this Article 6 of this Agreement or in , Transporter shall provide a credit to Shipper for any other provision of this Agreement such Mitigation which shall include an adjustment to the contrarycosts incurred by Transporter for the Mitigation. If Shipper is required to reimburse Transporter for Development Costs, with respect then Shipper shall have the right, upon at least five (5) business days prior written notice to activities on Transporter, to audit books and after records of Transporter relating to the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 Any such audit shall be conducted during normal business hours and at Shipper’s sole expense. Shipper shall have six (6) months after the date of this Agreement or receipt of an invoice for its share of the Development Costs (but in any other provision of this Agreement to the contrary, event Shipper shall have at least three (i3) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued months after Transporter closes its books with respect thereto, ) in which to complete such an audit and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments submit claims under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.this provision. 9

Development Costs. With respect to activities If prior to the Amendment Effective DateCommencement Date Transporter terminates this Agreement under Sections 5(A)(iv) or 5(A)(vi) or Shipper terminates this Agreement under Section 5(D)(iii) , each Party was to then Shipper shall pay [*] Transporter the actual costs reasonably incurred and/or committed by Transporter for the development of the total Direct Project (“Development Costs”). The Development Costs shall include, but shall not be limited to, all costs associated with the following activities: (i) participating in the FERC pre-filing process; (ii) preparing and filing Transporter’s application for a FERC Certificate; (iii) developing, designing, surveying, and performing studies to define the scope of a Product the Project; (iv) developing the design and engineering of the Project Facilities; (v) preparing all drawings, maps, reports, and schedules necessary to be included in Transporter’s application for the FERC Certificate; (vi) contacting and meeting with any and all stakeholders to gain support for, or to appease opposition to, the Project; (vii) preparing, filing, and processing all relevant applications for Transporter Regulatory Authorizations; (viii) identifying the suitability of the property on which the Project Facilities will be constructed and any construction areas that will be needed as part of the Project; and (ix) acquisition of equipment and materials for the construction any portion of the Project Facilities. To the extent that Shipper owes Transporter for Development Costs as provided in this Section 3(E), not later than ninety (90) days following the termination of this Agreement, Transporter shall deliver an invoice (“Invoice”) to Shipper for all Development Costs incurred in accordance with the terms hereof. The Invoice shall set forth all charges and credits (in United States Dollars) summarized by appropriate classifications indicating the nature of the charges. Within thirty (30) days after the receipt of the Invoice, Shipper shall pay Transporter all Development Budget (as defined Costs set forth in the Original AgreementInvoice. To the extent Transporter, using commercially reasonable efforts, is able to mitigate any of the Development Costs during a period of time that extends six (6) months from the date this Precedent Agreement is terminated (“Mitigation”). Notwithstanding anything in this Article 6 of this Agreement or in , Transporter shall provide a credit to Shipper for any other provision of this Agreement such Mitigation which shall include an adjustment to the contrarycosts incurred by Transporter for the Mitigation. If Shipper is required to reimburse Transporter for Development Costs, with respect then Shipper shall have the right, upon at least five (5) business days prior written notice to activities on Transporter, to audit books and after records of Transporter relating to the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 Any such audit shall be conducted during normal business hours and at Shipper’s sole expense. Shipper shall have six (6) months after the date of this Agreement or receipt of an invoice for its share of the Development Costs (but in any other provision of this Agreement to the contrary, event Shipper shall have at least three (i3) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued months after Transporter closes its books with respect thereto, ) in which to complete such an audit and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments submit claims under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforthis provision.

Development Costs. With respect to activities prior to the Amendment Effective Date, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed [*]-INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED WITH THE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.

Development Costs. With respect to activities prior to the Amendment Effective DateMedivation shall be responsible for fifty percent (50%) and Astellas shall be responsible for fifty percent (50%) of all Joint Development Costs, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, except with respect to activities on costs of Non-Clinical Studies and Clinical Trials (including the costs of drug product or comparator drug for use therein) and the costs of CMC Activities (a) contemplated in the Joint Development Plan and (b) reasonably considered to be required for receipt of Regulatory Approvals for Products in the Shared Territory and either or both of the EU and Japan, for which Medivation shall be responsible for one-third (1/3) and Astellas shall be responsible for two-thirds (2/3). Prior to the initiation of any Non-Clinical Study, Clinical Trial or CMC Activity commencing after the Amendment Effective DateDate supporting Development of Products with respect to the Shared Territory and either or both of the EU and Japan, subject the Parties shall agree whether the costs of such study or activity are to Sections 3.1.2, Alimera will be solely shared equally by the Parties or allocated pursuant to clause (b) above. Astellas shall be responsible for, and shall pay for one hundred percent (100%) of, of all development Development Costs for the Licensed Territory if such costs of a Product, including Direct are not included in Joint Development Costs. The allocation of costs for the Non-Clinical Studies and Clinical Trials contained in the Initial Joint Development Plan shall be as set forth therein. Notwithstanding anything the amounts allocated to Development activities in this Article 6 of this Agreement or in the applicable Joint Development Plan, for any other provision of this Agreement calendar year, Astellas and Medivation shall each be permitted to the contrary, (i) all payments owing by CDS hereunder recover Joint Development Costs with respect to development such Party’s Development activities prior for such year covered in the Joint Development Budget in excess of the amount allocated therein (x) by up to [*] of the Amendment Effective Date are hereby deemed fully paid by CDS (or waivedamount so allocated, but solely to the extent such waiver overage was outside the reasonable control of the applicable Party and was not attributable to a failure by the applicable Party to use commercially reasonable efforts to adequately supervise any Third Party performing such activities or (y) with the unanimous approval of the JDC, which approval may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined granted either in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as advance of such date; (ii) all payments owing by Alimera hereunder with respect costs being incurred or retroactively. The Parties shall reconcile the Joint Development Costs they have incurred to development activities prior reflect the foregoing allocation of Joint Development Costs according to the Amendment Effective Date are hereby deemed fully paid by Alimera (procedures in Section 9.2 or waivedSection 9.3, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforapplicable.

Development Costs. Except as otherwise set forth in this Section 3.4, BDSI shall be responsible for all costs and expenses incurred by it in connection with its performance of Clinical Trials of Product in the U.S. pursuant to the Development Plan hereunder, which shall only include any costs associated with the conduct of the *** for any of the foregoing, and BDSI’s internal operating costs with respect to any of the foregoing, such as costs of personnel and overhead therefor. “Development Costs” means ***. With respect to activities prior the ***, BDSI shall be responsible for the first $*** in Development Costs incurred by BDSI in connection therewith, Endo shall be responsible for the next $*** in Development Costs incurred by BDSI in connection therewith, and the Parties shall share equally in all Development Costs incurred by BDSI in connection therewith in excess of $*** (and, within *** of receiving any invoice from BDSI for any portion of Endo’s share of such Development Costs pursuant to the Amendment Effective Dateforegoing, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original AgreementEndo shall reimburse BDSI for such amount). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement BDSI shall have the right, upon written notice to the contrary, Endo with respect to activities on and after the Amendment Effective Dateany portion of Development Costs to be borne by BDSI hereunder, subject to Sections 3.1.2cause Endo to pay or reimburse BDSI such costs (any portion thereof to be paid by Endo within *** of an invoice therefor from BDSI), Alimera will ***. Endo shall also be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, for (i) all payments owing by CDS costs and expenses incurred in connection with the Post-Approval Development Activities, (ii) all Development Costs (and other costs) incurred in connection with the development of Product outside of the U.S. or any Clinical Trials other than the ***, and (iii) all costs associated with Post-Approval Regulatory Submissions as set forth in Section 4.2. For the purpose of clarity, except as otherwise specified in this Agreement, each Party shall be responsible for their own internal operating costs, such as personnel and overhead, in performing their obligations hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid development. *** Confidential Treatment Requested by CDS (or waivedBioDelivery Sciences International, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder Inc. IRS Employer Identification No. 35-208985 Confidential treatment requested with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued certain portions hereof denoted with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.“***”

Development Costs. With Medivation shall be responsible for fifty percent (50%) and Astellas shall be responsible for fifty percent (50%) of all Joint Development Costs, except with respect to activities prior costs of Non-Clinical Studies and Clinical Trials (including the costs of drug product or comparator drug for use therein) and the costs of CMC Activities (a) contemplated in the Joint Development Plan and (b) reasonably considered to be required for receipt of Regulatory Approvals for Products in the Amendment Effective DateShared Territory and either or both of the EU and Japan, each Party was to pay for which Medivation shall be responsible for one-third (1/3) and Astellas shall be responsible for two-thirds (2/3). [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the securities and exchange commission pursuant to rule 24b-2 of the total Direct Development Costs securities exchange act of a Product incurred in accordance with the Development Budget (1934, as defined in the Original Agreement)amended. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement Prior to the contraryinitiation of any Non-Clinical Study, Clinical Trial or CMC Activity commencing after the Effective Date supporting Development of Products with respect to activities on the Shared Territory and after either or both of the Amendment Effective DateEU and Japan, subject the Parties shall agree whether the costs of such study or activity are to Sections 3.1.2, Alimera will be solely shared equally by the Parties or allocated pursuant to clause (b) above. Astellas shall be responsible for, and shall pay for one hundred percent (100%) of, of all development Development Costs for the Licensed Territory if such costs of a Product, including Direct are not included in Joint Development Costs. The allocation of costs for the Non-Clinical Studies and Clinical Trials contained in the Initial Joint Development Plan shall be as set forth therein. Notwithstanding anything the amounts allocated to Development activities in this Article 6 of this Agreement or in the applicable Joint Development Plan, for any other provision of this Agreement calendar year, Astellas and Medivation shall each be permitted to the contrary, (i) all payments owing by CDS hereunder recover Joint Development Costs with respect to development such Party’s Development activities prior for such year covered in the Joint Development Budget in excess of the amount allocated therein (x) by up to [*] of the Amendment Effective Date are hereby deemed fully paid by CDS (or waivedamount so allocated, but solely to the extent such waiver overage was outside the reasonable control of the applicable Party and was not attributable to a failure by the applicable Party to use commercially reasonable efforts to adequately supervise any Third Party performing such activities or (y) with the unanimous approval of the JDC, which approval may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined granted either in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as advance of such date; (ii) all payments owing by Alimera hereunder with respect costs being incurred or retroactively. The Parties shall reconcile the Joint Development Costs they have incurred to development activities prior reflect the foregoing allocation of Joint Development Costs according to the Amendment Effective Date are hereby deemed fully paid by Alimera (procedures in Section 9.2 or waivedSection 9.3, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforapplicable.

Development Costs. With respect to activities prior Subject to the Amendment Effective Date, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 other provisions of this Agreement Agreement, Owners shall be responsible for the payment, without deduction or in any other provision setoff (except as otherwise expressly set forth herein), of this Agreement all costs incurred to develop and construct the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent Project (100%) of, all development costs of a Product, including Direct “Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary”) including, without limitation, (i) all payments owing by CDS hereunder amounts payable under any Construction Contract, architect agreement or other contract or agreement respecting the design and construction of the Project entered into in accordance with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waivedterms of this Agreement and the Related Documents, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder taxes payable with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera Project (or waivedother than income, to the extent such waiver may be requirednet profits and similar taxes), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) the premiums for all insurance required or permitted hereunder and carried by or on behalf of Developer with respect to the Project, (iv) all permit and approval fees incurred with respect to the Project, (v) the Development Fee, (vi) the Bonding Costs, and (vii) all other costs and expenses incurred by Developer in the performance of its obligations under this Agreement. Notwithstanding the foregoing (A) Owners shall not be required to pay for the aggregate amount of Guaranty Cost Items in respect of the Base Project Improvements and Hotel Furnishings which exceed the Base LEGAL\19062995\17 Project Guaranteed Maximum Development Price, and (B) Office Owner shall not be required to pay for the aggregate amount of Guaranty Cost Items in respect of the Tenant Improvements which, when added to amounts expended by Major Tenants (without duplication) for Guaranty Cost Items in respect of the Tenant Improvements, exceed the Tenant Improvements Guaranteed Maximum Development Price. Office Owner shall cause the Major Tenant to advance and pay pursuant to the terms of the Work Letter, subject to Sections 3.1.1 the rights of Major Tenant to object thereto and 3.1.2withhold payment under the Work Letter, from all costs and after payments which are the Amendment Effective DateMajor Tenant’s responsibility under the Work Letter. Notwithstanding anything to the contrary contained in this Agreement, CDS will have Owners shall not be deemed to be in default with respect to a monetary obligation under this Agreement so long as no liability whatsoever hereunder for any pastFunding Default exists. Title to all work, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date)materials, and instead Alimera equipment installed in or about the Project shall have sole liability pass to the Owner(s) and/or Major Tenant, as applicable, upon the applicable party’s receipt of payment therefor, free and clear of any liens, claims, security interests or encumbrances.

Development Costs. With respect to activities prior to Except as set forth in the Amendment Effective DateCo-Promotion Agreement, commencing with the Fiscal Quarter beginning January 1, 2009, and occurring each Party was Fiscal Quarter thereafter, the Parties agree to pay [*] the Development Costs for the development and Regulatory Approval of the total Direct Licensed Product in the Field of Use as follows: Allergan shall be responsible for sixty-five percent (65%) of Development Costs incurred by Spectrum and Allergan in performing their obligations hereunder, and Spectrum is responsible for thirty-five percent (35%) of the Development Costs incurred by Spectrum and Allergan in performing their obligations hereunder. Within the first five (5) business days of each Fiscal Quarter commencing on January 1, 2009, Allergan shall pay Spectrum quarterly in advance Allergan’s share of the estimated Development Costs which Spectrum is estimated to incur for such Fiscal Quarter (as set forth in the JDP). On a Product monthly basis the Parties agree to discuss the Development Costs incurred in accordance with the previous month and review tracking of actual Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement Costs to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct estimated Development Costs. Notwithstanding anything The Parties shall reconcile their respective applicable Development Costs, and will deliver to the other Party, by the third business day after the new Fiscal Quarter, the backup requested by such other Party to complete such other Party’s quarterly accounting close. The estimate provided by each Party on the third business day shall be materially correct as regards actual Development Costs incurred. Within thirty (30) days after the end of each Fiscal Quarter, Allergan will provide Spectrum with an invoice representing thirty-five percent (35%) of the Development Costs incurred by Allegan during the previous Fiscal Quarter and Spectrum will process a payment to Allergan within thirty (30) days following receipt of this invoice. Within thirty (30) days after the end of each Fiscal Quarter, Spectrum shall perform a true-up to determine its **** Certain confidential information contained in this Article 6 document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. actual Development Costs incurred during the previous Fiscal Quarter. If the true-up reflects actual Development Costs incurred in excess of advances previously made by Allergan, Spectrum will provide Allergan with an invoice representing the excess and Allergan will process a payment to Spectrum within thirty (30) days following receipt of this Agreement or in any other provision invoice. If the true-up reflects actual Development Costs incurred less than advances previously made by Allergan, Spectrum will reduce their next quarterly advance from Allergan by the amount of this Agreement to the contrary, (i) shortfall. Spectrum shall bear all payments owing by CDS hereunder with respect to Development Costs for development activities of the Licensed Product incurred prior to January 1, 2009. In the Amendment Effective Date are hereby deemed fully paid event of a Development Trigger after which Allergan delivers notice to Spectrum under Section 10.1 for Allergan to take over development, all of the Development Costs incurred by CDS (or waived, to Allergan in performing the extent such waiver may development and Regulatory Approval services itself shall also be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined borne by the Parties in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (iiratio(s) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined set forth in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforthis Section 6.6.

Development Costs. With Metroplex shall pay or advance to the Company all of the Development Costs incurred for developing each parcel of the Joint Venture Property and the Cable Property, to the extent provided in Section 8(c) of the Joint Contribution Agreement, until such parcel is subject to a binding commitment to be sold or leased (to a primary tenant) by the Company (a "Commitment"). All Development Costs paid or advanced to the Company by Metroplex with respect to activities prior a parcel before it is subject to a Commitment shall be promptly reported to the Amendment Effective DateCompany and, each Party was if such Development Costs (when added to pay [*] of previously reported and approved Development Costs) are within the total Direct amount of expenditures contemplated for the relevant line item category of expenditures in the relevant Development Budget, or are otherwise approved in writing by GCN, they shall be accounted for by the Company as Additional Capital Contributions by Metroplex; provided, however, that no such contributions shall affect the Percentage Interest or Voting Interest of Metroplex in the Company. In all such reports and requests for approval, Internal Development Costs shall be identified by Metroplex as separate line item components of a Product incurred in accordance with the its Development Budget (as defined in the Original Agreement)Costs. Notwithstanding anything in this Article 6 any contrary provision of this Agreement or the Joint Contribution Agreement, Metroplex shall not be required to incur any Development Costs that either (i) are not included in any other provision of this Agreement to the contrarysuch a Development Budget; or (ii) would generally be incurred, under commonly accepted practices for similar developments in Clarx Xxxnty, Nevada, with respect to activities on and a parcel after the Amendment Effective Date, it is subject to Sections 3.1.2a Commitment. Each Member may contribute from time to time as an Additional Capital Contribution such additional money or other property as the Appointing Members may agree in writing; provided, Alimera will however, that any Additional Capital Contribution of property (other than money) made pursuant to this paragraph shall be solely responsible for, subject to the terms and shall pay one hundred percent (100%) of, all development costs provisions of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Contribution Agreement or in any other provision of this Agreement to approved by the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to Board and the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS Appointing Members and executed by CDS the contributing Member and Alimera regarding deferral of payments under the Original Agreement as a Manager prior to delivery of such date; property. Except as otherwise provided in the paragraphs (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be requireda), (b) and (c) of this Section 6.3, if Additional Capital Contributions are not made equally by all Members, the Percentage Interests and Capital Accounts of each Member shall be equitably adjusted to account for any non-pro-rata Additional Capital Contributions on terms that shall be set forth in a Contribution Agreement approved by the Board and Members holding at least two-thirds of the Voting Interests (including at least any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original AgreementMember whose Interest would be adversely affected), and further including any penalties and interest signed as provided in the preceding paragraph, which might have accrued with respect thereto; and (iii) subject agreement shall serve as an amendment to Sections 3.1.1 and 3.1.2Section 5.2. Any such agreement may also equitably adjust the Members' Voting Interests. Additional Membership Interests may be granted only as permitted by Section 5.3. If an additional Membership Interest is granted, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera Section 5.2 shall have sole liability thereforbe appropriately amended.

Development Costs. With respect to Except as provided in Section 4.3, PRAECIS shall pay seventy-five percent (75%), and Synthelabo shall pay twenty-five percent (25%), of all Development Costs incurred in carrying out the Core Development Plan. The foregoing cost sharing provisions shall also apply if PRAECIS enters into an agreement with a Third Party under which such Third Party shall undertake PRAECIS' development activities prior pursuant to the Amendment Effective DateCore Development Plan, each Party was unless PRAECIS and Synthelabo shall agree otherwise. Synthelabo shall pay all Development Costs which are incurred in carrying out the Supplemental Development Plan, provided that PRAECIS shall reimburse Synthelabo for seventy-five percent (75%) of such Development Costs to pay [*] the extent the results of the total Direct Development Phase activities in respect of which such Development Costs were incurred are used to seek or obtain Registration Approvals or Reimbursement Approvals in the United States. If (i) PRAECIS or its licensee or sublicensee wishes to use both outside of a Product the Territory and outside of the United States the results of the Supplemental Development Studies obtained by Synthelabo in carrying out the Supplemental Development Plan and (ii) PRAECIS is not required hereunder to reimburse Synthelabo 75% of the Development Costs incurred in accordance connection with the such Supplemental Development Budget (as defined Studies, then PRAECIS and Synthelabo shall meet to negotiate in the Original Agreement). Notwithstanding anything in this Article 6 good faith an equitable sharing of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct such Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement Anything herein to the contrarycontrary notwithstanding, (i) all payments owing each of Synthelabo and PRAECIS shall have full and complete access to and use of the safety data of the other regarding each Licensed Product, and each may use the safety data of the other for Advertising and Promotion, in each case without any cost or reimbursement therefor and (ii) regulatory submission, registration fees and maintenance fees in the Territory shall be paid by CDS hereunder with respect Synthelabo, and registration fees and maintenance fees outside the Territory shall be paid by PRAECIS. If a party is claiming reimbursement pursuant to development activities prior this Section 4.5, then within forty-five (45) days after the end of a calendar quarter during which the Development Costs for which reimbursement is being claimed were incurred, a party will submit to the Amendment Effective Date are hereby deemed fully other a statement (each a "Development Cost Statement") itemizing in reasonable detail such Development Costs and setting forth the total amount, if any, of such Development Costs to be reimbursed by the other party pursuant to this Section 4.5. Such reimbursement amounts shall be paid by CDS within twenty (or waived20) days after receipt of a Development Cost Statement, except to the extent such waiver may be required)Development Cost Statement is being disputed in good faith. Except as otherwise provided herein, including any each party shall assume full responsibility for its own Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforCosts.

Development Costs. With respect The Parties shall each be responsible for their respective share, as defined in this Section 4.5, of all Joint Development Costs. Mundipharma shall be responsible for the "Mundipharma Share" of Joint Development Costs, which share shall initially be forty percent (40%) of the Joint Development Costs and shall become fifty percent (50%) of the Joint Development Costs (the "50/50 Threshold") (a) in the calendar quarter after Mundipharma receives Conditional Approval or (b) if such Conditional Approval is not obtained, the later of (i) the calendar quarter of the first Drug Approval in the EU of the Product in the Lead Indication or First Line PTCL, and (ii) the first calendar quarter in which the Development Cost Differential equals or exceeds fifteen million Dollars ($15,000,000); provided, if the Development Cost Differential does not equal or exceed fifteen million Dollars ($15,000,000) by December 31, 2019, then Allos shall be required to activities prior remit the difference between fifteen million Dollars ($15,000,000) and the Development Cost Differential as of such date to Mundipharma on or before January 31, 2020 and thereafter the Mundipharma Share shall be fifty percent (50%). For purposes of this Section 4.5, the "Development Cost Differential" means the difference between (A) the cumulative amount of Joint Development Costs borne by Mundipharma (whether as reimbursement to Allos pursuant to Section 7.2(a) or as Joint Development Costs directly incurred by Mundipharma to the Amendment Effective Date, each Party was to pay [*] of the total Direct extent that such Joint Development Costs of a Product incurred in accordance exceed Allos' reimbursement to Mundipharma pursuant to Section 7.2(b)), together with the Development Budget any Joint Manufacturing Costs (as defined in the Original Supply Agreement) borne by MMCO pursuant to the Supply Agreement, and (B) the cumulative amount of Joint Development Costs that Mundipharma would have borne if Mundipharma had been responsible for fifty percent (50%) of Joint Development Costs (rather than forty percent (40%) of Joint Development Costs). Notwithstanding anything , together with any Joint Manufacturing Costs (as defined in the Supply Agreement) that MMCO would have borne pursuant to the Supply Agreement if MMCO had been responsible for fifty percent (50%) (rather than forty percent (40%)) of Joint Manufacturing Costs under the Supply [ * ] = Certain confidential information contained in this Article 6 document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of this Agreement or in any the Securities Exchange Act of 1934, as amended. Agreement. Allos shall be responsible for the Allos Share of Joint Development Costs as well as for all costs and expenses of the Allos Studies. The Party conducting an Incremental Study shall be solely responsible for all costs and expenses of such Incremental Study, unless the other provision of this Agreement to the contrary, Party exercises its Opt-In Right with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything such study in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder accordance with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be requiredSection 4.4(c)(v), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.

Development Costs. With respect to activities prior to Except as set forth in the Amendment Effective DateCo-Promotion Agreement, commencing with the Fiscal Quarter beginning January 1, 2009, and occurring each Party was Fiscal Quarter thereafter, the Parties agree to pay [*] the Development Costs for the development and Regulatory Approval of the total Direct Licensed Product in the Field of Use as follows: Allergan shall be responsible for sixty-five percent (65%) of Development Costs incurred by Spectrum and Allergan in performing their obligations hereunder, and Spectrum is responsible for thirty-five percent (35%) of the Development Costs incurred by Spectrum and Allergan in performing their obligations hereunder. Within the first five (5) business days of each Fiscal Quarter commencing on January 1, 2009, Allergan shall pay Spectrum quarterly in advance Allergan’s share of the estimated Development Costs which Spectrum is estimated to incur for such Fiscal Quarter (as set forth in the JDP). On a Product monthly basis the Parties agree to discuss the Development Costs incurred in accordance with the previous month and review tracking of actual Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement Costs to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct estimated Development Costs. Notwithstanding anything The Parties shall reconcile their respective applicable Development Costs, and will deliver to the other Party, by the third business day after the new Fiscal Quarter, the backup requested by such other Party to complete such other Party’s quarterly accounting close. The estimate provided by each Party on the third business day shall be materially correct as regards actual Development Costs incurred. Within thirty (30) days after the end of each Fiscal Quarter, Allergan will provide Spectrum with an invoice representing thirty-five percent (35%) of the Development Costs incurred by Allegan during the previous Fiscal Quarter and Spectrum will process a payment to Allergan within thirty (30) days following receipt of this invoice. Within thirty (30) days after the end of each Fiscal Quarter, Spectrum shall perform a true-up to determine its actual Development Costs incurred during the previous Fiscal Quarter. If the true-up reflects actual Development Costs incurred in excess of advances previously made by Allergan, Spectrum will provide Allergan with an invoice representing the excess and Allergan will process a payment to Spectrum within thirty (30) days following receipt of this invoice. If the true-up reflects actual Development Costs incurred less than advances previously made by Allergan, Spectrum will reduce their next quarterly advance from Allergan by the amount of the shortfall. Spectrum shall bear all Development Costs for development of the Licensed Product incurred prior to January 1, 2009. In the event of a Development Trigger after which Allergan delivers notice to Spectrum under Section 10.1 for Allergan to take over development, all of the Development Costs incurred by Allergan in performing the development and Regulatory Approval services itself shall also be borne by the Parties in the ratio(s) set forth in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforSection 6.6.

Development Costs. With Each of the Initial Projects shall be reviewed prior to any expenditure by the Joint Venture Management Committee. The Parties acknowledge that NWP has incurred development costs with respect to activities the Initial Projects prior to July 31, 1996 of $2.5 million. Subject to the approval requirements for expenditures provided below, in consideration of DBP's receiving a 50% equity interest in the Initial Projects DBP shall pay with respect to the Initial Projects specified on Exhibit A hereto up to $2.5 million (the "Initial Funding Commitment") to equal the amount of development costs for which NWP has received credit pursuant to the first sentence of this paragraph; provided, however, (i) that the Initial Funding Commitment shall be reduced by the amount of unexpended development costs to be funded by DBP with respect to Initial Projects which are abandoned by the Management Committee and (ii) in no event shall the Initial Funding Commitment be less than $500,000 (including Development Costs of approximately $130,000 incurred prior by DBP prior to the Amendment Effective Date, each Party was to pay [*] date of this Agreement). Within five days of the total Direct Development Costs execution of a Product incurred this Agreement, DBP shall deposit into an escrow account $400,000 to be earmarked exclusively for the development of the Texas Project. The Initial Funding Commitment shall be satisfied by the payment by DBP of costs related to Projects in accordance with the Development Budget (Project budget. Except as defined DBP shall determine in the Original its sole discretion, prior to any funding of a Project pursuant to this Agreement), NWP shall execute bills of sale and such instruments of transfer as DBP shall reasonably request so as to effect DBP's purchase of a 50% interest in each such Project. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, Except as set above with respect to activities DBP's commitment of development costs with respect to the Initial Projects, the Parties shall share all project development costs equally, with NWP being responsible for the development costs which will be incurred prior to acceptance of a Project by the Joint Venture, DBP being responsible for the next portion of development costs equal to NWP's initial contribution and the Parties being responsible for the remaining development costs on a 50/50 basis. Development costs shall only be incurred at the direction of the Management Committee and after until a Party declines, in its sole discretion, to participate in the Amendment Effective Datedevelopment of such project, or a Party or the Joint Venture or a Project Entity abandons or transfers its interest in a Project, or a Party is otherwise required to discontinue its participation in a Project. Development costs include out-of-pocket, third-party expenses reasonably incurred by the Parties in furtherance of development of a Project as well as the cost associated with employees and consultants of the Parties who perform work to develop a power project, as provided below. In no event shall the reimbursable costs for employees and consultants of a Party or an affiliate thereof be credited in excess of an hourly rate which exceeds 1.4 times the hourly equivalent wage in the case of an employee or 1.1 times the hourly fee of a consultant retained by such Party, in each case for the actual time period involved by such staff in Joint Venture development activities. Each Party shall be required to submit detailed time sheets setting forth the tasks performed by the employees and/or consultants in respect of Joint Venture activities. It is anticipated that NWP employees and consultants will perform a majority of the development activities. DBP shall have the ability, however, to dedicate up to one full-time equivalent employee to Joint Venture activities, subject to Sections 3.1.2, Alimera will be solely responsible for, agreement by the Parties as appropriate concerning time commitment and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued cost reimbursement arrangements with respect thereto. Each Party shall submit bills (and provide all reasonably requested supporting documentation) for development costs incurred after July 31, 1996 on a monthly basis and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as each Party's share of such date; (ii) all payments owing by Alimera hereunder with respect costs shall be payable within 30 days of submission of such bills. Semiannually, the Parties shall review and reconcile any development costs incurred hereunder. Verified development costs shall be recovered at project financial closing unless converted to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (equity or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined subordinated debt in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability thereforprojects.